General information
Formycon AG
Fraunhoferstraße 15
82152 Martinsried/Planegg, Bavaria
Germany
Contact person: Stefan Glombitza, Chief Executive Officer
Company main phone: +49 (89) 864667100
Company main fax: +49 (89) 864667110
Website: https://www.formycon.com
Year founded: | 1999
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 239 |
Corporate description / mission:
Formycon is a developer of biopharmaceutical medicines, especially biosimilars. The company is focused on the treatments in ophthalmology, immunology and on other key chronic diseases. The company's biosimilar candidates are FYB201, FYB202, FYB203 etc. Formycon is making an important contribution to providing as many patients as possible with access to effective and affordable medicines.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2012
Categorization
Sector: |
- Pharma (fully integrated)
|
Subsector: |
- Anti-infectives
- Biosimilars
- Immunotherapy
|
Primary therapeutic areas: |
- Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
- Diseases of the eye / ophthalmology
- Infectious and parasitic diseases / infectiology / parasitology
- Neoplasms / cancer / oncology
- Skin and subcutaneous tissue / dermatology
- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
- Small biotech
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 4 | |
Phase I: | 1 | |
On the market: | 7 | |
Description of products:
FYB201
FYB202
FYB203
FYB207 etc.
Financing details
Market cap. / valuation: | USD 875.40M | |